Wild-type and mutated IDH1/2 enzymes and therapy responses

被引：175
|
作者：
Molenaar, Remco J. [1 ,2 ,3 ]
Maciejewski, Jaroslaw P. [3 ]
Wilmink, Johanna W. [2 ]
van Noorden, Cornelis J. F. [1 ]
机构：
[1] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Biol, Amsterdam, Netherlands
[2] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
[3] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA
来源：
ONCOGENE | 2018年 / 37卷 / 15期
基金：
美国国家卫生研究院;
关键词：
ACUTE MYELOID-LEUKEMIA; ISOCITRATE DEHYDROGENASE 1; PREDICT LONGER SURVIVAL; DNA-REPAIR ENZYMES; LOW-GRADE GLIOMAS; MUTANT IDH1; INTRAHEPATIC CHOLANGIOCARCINOMA; OXIDATIVE STRESS; TUMOR-CELLS; IN-VIVO;
D O I：
10.1038/s41388-017-0077-z
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of D-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.
引用
收藏
页码：1949 / 1960
页数：12
相关论文
共 50 条
  • [21] IDH1-mutated gliomas rely on anaplerosis of glutamate and lactate whereas IDH1 wild-type gliomas rely on glycolysis and acetate anaplerosis
    Khurshed, Mohammed
    Lenting, Krissie
    Peeters, Tom
    Molenaar, Remco J.
    Leenders, William
    van Noorden, Cornelis
    FASEB JOURNAL, 2018, 32 (01):
  • [22] IDH1-mutated gliomas rely on anaplerosis of glutamate and lactate whereas IDH1 wild-type gliomas rely on glycolysis and acetate anaplerosis
    Khurshed, Mohammed
    Lenting, Krissie
    Molenaar, Remco J.
    Leenders, William P.
    van Noorden, Cornelis J.
    CANCER RESEARCH, 2017, 77
  • [23] Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study
    Niger, Monica
    Nichetti, Federico
    Casadei-Gardini, Andrea
    Rizzato, Mario Domenico
    Pircher, Chiara
    Bini, Marta
    Franza, Andrea
    Rimini, Margherita
    Burgio, Valentina
    Sposetti, Caterina
    Fornaro, Lorenzo
    Rapposelli, Ilario Giovanni
    D'Amico, Francesco Enrico
    Aprile, Giuseppe
    Vivaldi, Caterina
    Frassineti, Giovanni Luca
    Milione, Massimo
    Leoncini, Giuseppe
    Cappetta, Alessandro
    Vasile, Enrico
    Fassan, Matteo
    Morano, Federica
    Perrone, Federica
    Tamborini, Elena
    Pruneri, Giancarlo
    Lonardi, Sara
    Mazzaferro, Vincenzo
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    de Braud, Filippo
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (08) : 1310 - 1320
  • [24] The Preclinical Efficacy Of Ketogenic Diet In IDH1 Wild-type And Mutant Gliomas
    Javier, Rodrigo
    Mirkov, Snezana
    Horbinski, Craig
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2020, 79 (06): : 667 - 667
  • [25] MYELOID-ASSOCIATED WILD-TYPE IDH1 PROMOTES IMMUNOSUPPRESSION IN GLIOBLASTOMA
    Dussold, Corey
    Tripathi, Shashwat
    Mahajan, Akanksha
    Tommasini-Ghelfi, Serena
    Hurley, Lisa
    Jarvis, Rachel
    Najem, Hinda
    Chalastanis, Alexandra
    Sooreshjani, Moloud
    Du, Ruochen
    Mccornack, Colin
    Giles, David
    Turunen, Jillyn
    Billingham, Leah
    Kim, Seunghyun
    Broom, Wendy
    Dadali-Abel, Tulin
    Murnan, Kevin
    Horbinski, Craig
    Thorp, Edward
    Kim, Albert
    Li, Yang
    Miska, Jason
    Heimberger, Amy
    Stegh, Alexander
    NEURO-ONCOLOGY, 2024, 26
  • [26] Wild-type IDH1 inhibition enhances chemotherapy response in pancreatic cancer
    Zarei, Mehrdad
    Hajihassani, Omid
    Hue, Jonathan J.
    Graor, Hallie J.
    Loftus, Alexander W.
    Rothermel, Luke D.
    Winter, Jordan M.
    CANCER RESEARCH, 2024, 84 (02)
  • [27] CHARACTERIZATION OF DIFFERENTIAL 5-HYDROXYMETHYLCYTOSINE IN IDH1 MUTANT VERSUS IDH1 WILD-TYPE HIGH-GRADE GLIOMAS
    Glowacka, Wioletta
    Jain, Harshika
    Okura, Makiko
    Maimaitiming, Abulizi
    Yasin, Mamatjan
    Farooq, Hamza
    Aldape, Kenneth
    Kongkham, Paul
    NEURO-ONCOLOGY, 2017, 19 : 95 - 95
  • [28] In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma
    Khurshed, Mohammed
    Molenaar, Remco J.
    Lenting, Krissie
    Leenders, William P.
    van Noorden, Cornelis J. F.
    ONCOTARGET, 2017, 8 (30) : 49165 - 49177
  • [29] Genomic Profiling Reveals Distinctive Molecular Relapse Patterns in IDH1/2 Wild-Type Glioblastoma
    Riehmer, Vera
    Gietzelt, Jens
    Beyer, Ulrike
    Hentschel, Bettina
    Westphal, Manfred
    Schackert, Gabriele
    Sabel, Michael C.
    Radlwimmer, Bernhard
    Pietsch, Torsten
    Reifenberger, Guido
    Weller, Michael
    Weber, Ruthild G.
    Loeffler, Markus
    GENES CHROMOSOMES & CANCER, 2014, 53 (07): : 589 - 605
  • [30] Why not wild-type IDH1? Finding novel chemical matter for the forgotten isotype
    Jakob, Clarissa G.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2019, 75 : A58 - A58
12345